{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:43:05Z","timestamp":1791852185749,"version":"4.3.4"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            S-649266 is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Two sets of clinical isolate collections were used to evaluate the antimicrobial activity of S-649266 against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            . These sets included 617 global isolates collected between 2009 and 2011 and 233 \u03b2-lactamase-identified isolates, including 47 KPC-, 49 NDM-, 12 VIM-, and 8 IMP-producers. The MIC\n            <jats:sub>90<\/jats:sub>\n            values of S-649266 against the first set of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Serratia marcescens<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Citrobacter freundii<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacter aerogenes<\/jats:named-content>\n            , and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacter cloacae<\/jats:named-content>\n            isolates were all \u22641 \u03bcg\/ml, and there were only 8 isolates (1.3%) among these 617 clinical isolates with MIC values of \u22658 \u03bcg\/ml. In the second set, the MIC values of S-649266 were \u22644 \u03bcg\/ml against 109 strains among 116 KPC-producing and class B (metallo) carbapenemase-producing strains. In addition, S-649266 showed MIC values of \u22642 \u03bcg\/ml against each of the 13 strains that produced other types of carbapenemases such as SME, NMC, and OXA-48. The mechanisms of the decreased susceptibility of 7 class B carbapenemase-producing strains with MIC values of \u226516 \u03bcg\/ml are uncertain. This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            , including strains that produce carbapenemases such as KPC and NDM-1.\n          <\/jats:p>","DOI":"10.1128\/aac.01695-15","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T02:33:37Z","timestamp":1447727617000},"page":"729-734","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":239,"title":["<i>In Vitro<\/i>\n            Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains"],"prefix":"10.1128","volume":"60","author":[{"given":"Naoki","family":"Kohira","sequence":"first","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"West","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Ito","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ito-Horiyama","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rittenhouse","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratory for Core Therapeutic Areas, Shionogi &amp; Co., Ltd., Toyonaka, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. 2014. Antimicrobial resistance global report on surveillance. World Health Organization Geneva Switzerland. http:\/\/www.thehealthwell.info\/node\/763364."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2006.05.005"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.1.49"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3203-3206.2004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.06.012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00763.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568005043340623"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Glasner C Albiger B Buist G Tambi\u0107 Andrasevi\u0107 A Canton R Carmeli Y Friedrich AW Giske CG Glupczynski Y Gniadkowski M Livermore DM Nordmann P Poirel L Rossolini GM Seifert H Vatopoulos A Walsh T Woodford N Donker T Monnet DL Grundmann H European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. 2013. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries February 2013. Euro Surveill 18:pii=20525. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20525.","DOI":"10.2807\/1560-7917.ES2013.18.28.20525"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2014.04.009"},{"key":"e_1_3_2_12_2","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention Atlanta GA. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/."},{"key":"e_1_3_2_13_2","unstructured":"European Centre for Disease Prevention and Control. 2013. ECDC reviews-US CDC report on antibiotic resistance threats in the United States 2013. European Centre for Disease Prevention and Control Solna Sweden. http:\/\/ecdc.europa.eu\/en\/activities\/sciadvice\/_layouts\/forms\/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=752."},{"key":"e_1_3_2_14_2","volume-title":"S-649266, a novel siderophore cephalosporin: Binding affinity to PBP and bactericidal activity","author":"Ito A","year":"2015","unstructured":"Ito A, Nishikawa T, Oota M, Kanazawa S, Fukuhara N, Yamaguchi T, Nakamura R, Tsuji M, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: Binding affinity to PBP and bactericidal activity, abstr ECCMID-1871. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-009-9219-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)01030-4"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01345-12"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.613"},{"key":"e_1_3_2_20_2","volume-title":"S-649266, a novel siderophore cephalosporin: III. Stability against clinically relevant \u03b2-lactamases","author":"Ishii Y","year":"2014","unstructured":"Ishii Y, Tateda K, Horiyama T, Tsuji M, Yamano Y, Shimada J, Yamaguchi K. 2014. S-649266, a novel siderophore cephalosporin: III. Stability against clinically relevant \u03b2-lactamases, abstr F-1557. Abstr 54th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_21_2","volume-title":"CLSI document M07-A8","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20148th ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2015.07.005"},{"key":"e_1_3_2_23_2","volume-title":"Comparative in vitro activity of PTX2416, a dihydroxypyridone monobactam, against Gram-negative clinical isolates","author":"Gill AE","year":"2003","unstructured":"Gill AE, Taylor K, Lewendon A, Unemi N, Uji T, Nishida K, Salama S, Singh R, Micetich RG. 2003. Comparative in vitro activity of PTX2416, a dihydroxypyridone monobactam, against Gram-negative clinical isolates, abstr F-552. Abstr 43rd Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_24_2","volume-title":"CLSI M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1879"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00206-15"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-15"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.06.011"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2013.86"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.017"},{"key":"e_1_3_2_31_2","volume-title":"S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models","author":"Nakamura R","year":"2014","unstructured":"Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models, abstr F-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01695-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01695-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:28:46Z","timestamp":1645475326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01695-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1128\/AAC.01695-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01695-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2015-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}